TARA
Protara Therapeutics, Inc. NASDAQ Listed Oct 22, 2014$5.66
After hrs
$5.74
+1.41%
Mkt Cap $218.4M
52w Low $2.77
57.2% of range
52w High $7.82
50d MA $5.37
200d MA $5.05
P/E (TTM)
-4.0x
EV/EBITDA
-2.8x
P/B
1.2x
Debt/Equity
0.0x
ROE
-29.2%
P/FCF
-4.0x
RSI (14)
—
ATR (14)
—
Beta
1.50
50d MA
$5.37
200d MA
$5.05
Avg Volume
923.8K
About
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacem…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | AMC | -0.32 | -0.37 | -15.6% | 5.71 | -1.1% | -1.9% | -6.8% | -7.9% | -5.1% | -4.6% | — |
| Nov 10, 2025 | AMC | -0.39 | -0.31 | +20.5% | 4.53 | +1.1% | +18.3% | +17.0% | +16.3% | +21.6% | +23.0% | — |
| Aug 11, 2025 | AMC | -0.43 | -0.35 | +18.6% | 3.10 | +1.3% | -1.0% | +5.2% | +2.9% | -2.3% | +3.9% | — |
| May 8, 2025 | AMC | -0.47 | -0.29 | +38.3% | 3.37 | +0.0% | -3.9% | -3.0% | -4.5% | -7.1% | -7.7% | — |
| Mar 5, 2025 | AMC | -0.57 | -0.48 | +15.8% | 3.63 | +0.6% | +8.0% | +10.7% | +3.3% | +12.9% | +12.1% | — |
| Nov 12, 2024 | AMC | -0.50 | -0.50 | +0.0% | 2.58 | +1.2% | +4.3% | +0.0% | -4.3% | -10.5% | -10.1% | — |
| Aug 6, 2024 | AMC | -0.82 | -0.45 | +45.1% | 2.07 | +4.3% | -8.2% | -8.2% | -8.2% | -6.3% | -7.7% | — |
| May 2, 2024 | AMC | -0.99 | -0.97 | +2.0% | 2.89 | +0.7% | +0.7% | +0.3% | -0.7% | -2.1% | +3.1% | — |
| Mar 13, 2024 | AMC | -1.03 | -0.90 | +12.6% | 3.65 | +1.4% | -2.2% | +0.8% | +9.6% | +9.6% | +10.4% | — |
| Nov 3, 2023 | AMC | -1.10 | -0.87 | +20.9% | 1.35 | +4.4% | +1.5% | -11.9% | -11.9% | -11.9% | -11.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.48 | $6.41 | -1.1% | -0.6% | +0.0% | +0.8% | +0.5% | +1.1% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.22 | $6.72 | +8.0% | +9.3% | +10.5% | -10.3% | -8.0% | -7.7% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.75 | $6.38 | -5.5% | -0.6% | -4.6% | +7.6% | +9.2% | +12.0% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.32 | $4.09 | -5.3% | -18.5% | -21.3% | -19.0% | -19.9% | -17.1% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.63 | $3.65 | +0.6% | +8.0% | +10.7% | +3.3% | +12.9% | +12.1% |
| Dec 6 | Guggenheim | Maintains | Buy → Buy | — | $6.02 | $5.66 | -6.0% | -1.8% | +10.8% | +3.8% | +3.8% | +3.8% |
| Dec 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.02 | $5.66 | -6.0% | -1.8% | +10.8% | +3.8% | +3.8% | +3.8% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.69 | $2.78 | +3.3% | -4.1% | -8.2% | -14.1% | -13.8% | -14.1% |
| Aug 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.90 | $1.91 | +0.5% | +2.1% | +0.5% | +4.2% | +7.9% | +5.8% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.90 | $1.96 | +3.2% | +0.0% | +0.0% | +2.1% | +0.5% | +4.2% |
Recent Filings
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Protara disclosed material information via Regulation FD, suggesting a significant announcement (likely clinical, partnership, or financial news) that could immediately impact stock valuation and trading behavior.
Mar 30
8-K
Unknown — 8-K Filing
Taravant's clinical progress and anticipated 2026 milestones suggest potential catalysts for value creation, but investors should await actual regulatory approvals or trial data before committing capital to this cash-burning biotech.
Mar 10
8-K · 8.01
!! High
Protara Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Protara Therapeutics presented clinical trial data for TARA-002 showing efficacy results in BCG-unresponsive and BCG-naïve bladder cancer patients, with preliminary response assessments completed across both patient populations.
Feb 24
Data updated apr 27, 2026 3:58am
· Source: massive.com